• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

New Test Could Predict Breast Cancer Risk

Article

The scientists at Cancer Research UK, in collaboration with the University of Cambridge, have identified 77 changes in the DNA of individuals at an increased risk for breast cancer and have developed a "polygenic risk score" based on the changes.

UK researchers have taken a step towards identifying women at increased risk of breast cancer by analysing their DNA (link is external).

The findings suggest that developing a test for a group of DNA changes could one day help doctors detect those with an increased risk of the disease. Improving the accuracy of risk analysis in this way could help tailor screening in the future, and serve as a guide for information and support given to women. The team, led by scientists at the Institute of Cancer Research and the University of Cambridge, analysed 77 individual DNA changes that have been linked with slight increases in breast cancer risk on their own.

But the increased risk is smaller than for other genetic faults, such as inherited changes in the BRCA1 and BRCA2 genes that can increase a woman’s risk of breast cancer by up to 90%. Studying data from 65,000 women, the researchers came up with a measure of risk — called a ‘polygenic risk score’ – based on the appearance of faults in these 77 regions. Using one of the world’s biggest databases of genetic information – called the Collaborative Oncological Gene-Environment Study – they found a link between higher ‘polygenic risk scores’ and a woman’s risk of breast cancer.

Link to the news report by Cancer Research UK: http://bit.ly/1NZ5Ojs

Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Will Shapiro, vice president of data science, Flatiron Health
Jonathan E. Levitt, Esq, Frier Levitt, LLC
Judy Alberto, MHA, RPh, BCOP, Community Oncology Alliance
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.